Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1723528rdf:typepubmed:Citationlld:pubmed
pubmed-article:1723528lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:1723528lifeskim:mentionsumls-concept:C0024897lld:lifeskim
pubmed-article:1723528lifeskim:mentionsumls-concept:C0033567lld:lifeskim
pubmed-article:1723528lifeskim:mentionsumls-concept:C0072257lld:lifeskim
pubmed-article:1723528lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:1723528lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:1723528lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:1723528lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:1723528lifeskim:mentionsumls-concept:C0165099lld:lifeskim
pubmed-article:1723528pubmed:issue3lld:pubmed
pubmed-article:1723528pubmed:dateCreated1992-3-12lld:pubmed
pubmed-article:1723528pubmed:abstractTextThe prostacyclin (PGI2) analogues, TEI-9063 and its methyl ester, TEI-1324, have been compared with another stable analogue, iloprost, with respect to binding to the PGI2 receptor, stimulation of adenylate cyclase activity and inhibition of thrombin-induced Ca2+ mobilization in mastocytoma P-815 cells. TEI-9063 displaced the [3H]iloprost binding to the membrane fraction, the IC50 value being 3 nM, but showed very low affinity for the PGE receptor. TEI-9063 dose dependently stimulated cAMP formation in the cells and GTP-dependent adenylate cyclase activity in the membrane fraction, the EC50 value being 50 and 10 nM, respectively. Furthermore, TEI-9063 prevented the thrombin-induced increase in the intracellular Ca2+ concentration, the IC50 value being 50 nM. These IC50 and EC50 values are lower than those obtained for iloprost. On the other hand, those of TEI-1324 were about two-orders higher. Although PGI2 lost its ability to stimulate cAMP formation by preincubation for 20 min at 37 degrees C, TEI-9063 completely retained its ability after 60-min preincubation. These results demonstrate that TEI-9063 is a stable and stronger agonist for the PGI2 receptor than iloprost, and that it prevents thrombin-induced Ca2+ mobilization through stimulation of the adenylate cyclase system in mastocytoma cells.lld:pubmed
pubmed-article:1723528pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:languageenglld:pubmed
pubmed-article:1723528pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:citationSubsetIMlld:pubmed
pubmed-article:1723528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1723528pubmed:statusMEDLINElld:pubmed
pubmed-article:1723528pubmed:monthSeplld:pubmed
pubmed-article:1723528pubmed:issn0090-6980lld:pubmed
pubmed-article:1723528pubmed:authorpubmed-author:HashimotoHHlld:pubmed
pubmed-article:1723528pubmed:authorpubmed-author:IchikawaAAlld:pubmed
pubmed-article:1723528pubmed:authorpubmed-author:KurozumiSSlld:pubmed
pubmed-article:1723528pubmed:authorpubmed-author:NegishiMMlld:pubmed
pubmed-article:1723528pubmed:authorpubmed-author:YatsunamiKKlld:pubmed
pubmed-article:1723528pubmed:issnTypePrintlld:pubmed
pubmed-article:1723528pubmed:volume42lld:pubmed
pubmed-article:1723528pubmed:ownerNLMlld:pubmed
pubmed-article:1723528pubmed:authorsCompleteYlld:pubmed
pubmed-article:1723528pubmed:pagination225-37lld:pubmed
pubmed-article:1723528pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:meshHeadingpubmed-meshheading:1723528-...lld:pubmed
pubmed-article:1723528pubmed:year1991lld:pubmed
pubmed-article:1723528pubmed:articleTitleTEI-9063, a stable and highly specific prostacyclin analogue for the prostacyclin receptor in mastocytoma P-815 cells.lld:pubmed
pubmed-article:1723528pubmed:affiliationDepartment of Physiological Chemistry, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.lld:pubmed
pubmed-article:1723528pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1723528pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1723528lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1723528lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1723528lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1723528lld:pubmed